Adverse Events with the Influenza A(H1N1) Vaccine Pandemrix® at Healthcare Professionals in Portugal
Autor(a) principal: | |
---|---|
Data de Publicação: | 2013 |
Outros Autores: | , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/4102 |
Resumo: | Introduction: Healthcare professionals were a priority group for Pandemrix® vaccination. Surveying this particularly committed group for vaccination related side effects could help to get valuable information about vaccine safety profile. Our aim was to identify the adverse events following immunization with Pandemrix® among healthcare professionals. Material and Methods: A questionnaire for active post-authorization monitoring of adverse events following immunization with the influenza vaccine A (H1N1) was designed and distributed to the vaccinated healthcare professionals working at 3 elected hospital centres in the Northern region, in the period from 26 October 2009 to 31 January 2010. Results: From the 2358 vaccinated healthcare professionals that accepted to participate in this study, 864 (37%) returned back the fulfill questionnaire on time. Among these, 634 (73%) of healthcare professionals experienced at least one adverse event following immunization, but only 8% experienced an unexpected one. The adverse events most frequently reported were expected and very common: local reactions at the injection site (57%), myalgia (31%), fatigue (including asthenia) (24%) and headache (19%). No cases of major episodes, such as death or life-threatening events were reported. Female gender and existence of underlying conditions were independent risk factors to develop at least one adverse event following immunization to the pandemic vaccine. Conclusions: Our work suggests an acceptable safety profile of this pandemic flu vaccine among healthcare professionals. Both frequency and severity of the observed adverse event following immunization do not seem to be higher than expected. |
id |
RCAP_03b375708b057dac212b3d7ef78be227 |
---|---|
oai_identifier_str |
oai:ojs.www.actamedicaportuguesa.com:article/4102 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Adverse Events with the Influenza A(H1N1) Vaccine Pandemrix® at Healthcare Professionals in PortugalEventos Adversos com a Vacina Pandemrix® Contra o Vírus Influenza A(H1N1) em Profissionais de Saúde em PortugalIntroduction: Healthcare professionals were a priority group for Pandemrix® vaccination. Surveying this particularly committed group for vaccination related side effects could help to get valuable information about vaccine safety profile. Our aim was to identify the adverse events following immunization with Pandemrix® among healthcare professionals. Material and Methods: A questionnaire for active post-authorization monitoring of adverse events following immunization with the influenza vaccine A (H1N1) was designed and distributed to the vaccinated healthcare professionals working at 3 elected hospital centres in the Northern region, in the period from 26 October 2009 to 31 January 2010. Results: From the 2358 vaccinated healthcare professionals that accepted to participate in this study, 864 (37%) returned back the fulfill questionnaire on time. Among these, 634 (73%) of healthcare professionals experienced at least one adverse event following immunization, but only 8% experienced an unexpected one. The adverse events most frequently reported were expected and very common: local reactions at the injection site (57%), myalgia (31%), fatigue (including asthenia) (24%) and headache (19%). No cases of major episodes, such as death or life-threatening events were reported. Female gender and existence of underlying conditions were independent risk factors to develop at least one adverse event following immunization to the pandemic vaccine. Conclusions: Our work suggests an acceptable safety profile of this pandemic flu vaccine among healthcare professionals. Both frequency and severity of the observed adverse event following immunization do not seem to be higher than expected.Introdução: Os profissionais de saúde foram um grupo prioritário para vacinação contra a pandemia da Gripe A (H1N1), Pandemrix®. Assim, monitorizar os eventos adversos relacionados com esta vacina neste grupo específico poderá originar informação valiosa relacionada com o perfil de segurança da vacina. O nosso objetivo foi identificar os eventos adversos após imunização com a vacina Pandemrix® em profissionais de saúde. Material e Métodos: Foi desenhado um questionário de monitorização dos eventos adversos ocorridos com a vacina Pandemrix®. O questionário foi distribuído aos profissionais de saúde a trabalhar em três centros hospitalares da região norte do País, vacinados no período de 26 de Outubro de 2009 a 31 de janeiro de 2009. Resultados: Dos 2358 profissionais de saúde que aceitaram participar no estudo, 864 (37%) devolveram o questionário preenchido. Destes, 73% experienciaram pelo menos um evento adverso após imunização, mas só 8% experienciaram um evento inesperado. Os eventos adversos mais frequentemente reportados foram os esperados e muito comuns: reações locais no local de administração (57%), mialgia (31%), fadiga (incluindo astenia) (24%) e dor de cabeça (19%). Não foram reportados casos de eventos de maior gravidade para a saúde, tais como morte ou risco de vida. O género feminino e a existência de doença de base foram fatores de risco independentes para o desenvolvimento de pelo menos um evento adverso após imunização com a Pandemrix®. Conclusões: O nosso trabalho sugere um perfil de segurança aceitável da vacina pandémica Pandermix® em profissionais de saúde. Tanto a frequência como a severidade dos eventos adversos não se verificaram superiores ao esperado.Ordem dos Médicos2013-05-31info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/4102oai:ojs.www.actamedicaportuguesa.com:article/4102Acta Médica Portuguesa; Vol. 26 No. 2 (2013): March-April; 107-112Acta Médica Portuguesa; Vol. 26 N.º 2 (2013): Março-Abril; 107-1121646-07580870-399Xreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPenghttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/4102https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/4102/3234Marques, Joana IsabelRibeiro Vaz, InêsSantos, CristinaPolónia, Jorgeinfo:eu-repo/semantics/openAccess2022-12-20T11:03:15Zoai:ojs.www.actamedicaportuguesa.com:article/4102Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T16:18:41.697261Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Adverse Events with the Influenza A(H1N1) Vaccine Pandemrix® at Healthcare Professionals in Portugal Eventos Adversos com a Vacina Pandemrix® Contra o Vírus Influenza A(H1N1) em Profissionais de Saúde em Portugal |
title |
Adverse Events with the Influenza A(H1N1) Vaccine Pandemrix® at Healthcare Professionals in Portugal |
spellingShingle |
Adverse Events with the Influenza A(H1N1) Vaccine Pandemrix® at Healthcare Professionals in Portugal Marques, Joana Isabel |
title_short |
Adverse Events with the Influenza A(H1N1) Vaccine Pandemrix® at Healthcare Professionals in Portugal |
title_full |
Adverse Events with the Influenza A(H1N1) Vaccine Pandemrix® at Healthcare Professionals in Portugal |
title_fullStr |
Adverse Events with the Influenza A(H1N1) Vaccine Pandemrix® at Healthcare Professionals in Portugal |
title_full_unstemmed |
Adverse Events with the Influenza A(H1N1) Vaccine Pandemrix® at Healthcare Professionals in Portugal |
title_sort |
Adverse Events with the Influenza A(H1N1) Vaccine Pandemrix® at Healthcare Professionals in Portugal |
author |
Marques, Joana Isabel |
author_facet |
Marques, Joana Isabel Ribeiro Vaz, Inês Santos, Cristina Polónia, Jorge |
author_role |
author |
author2 |
Ribeiro Vaz, Inês Santos, Cristina Polónia, Jorge |
author2_role |
author author author |
dc.contributor.author.fl_str_mv |
Marques, Joana Isabel Ribeiro Vaz, Inês Santos, Cristina Polónia, Jorge |
description |
Introduction: Healthcare professionals were a priority group for Pandemrix® vaccination. Surveying this particularly committed group for vaccination related side effects could help to get valuable information about vaccine safety profile. Our aim was to identify the adverse events following immunization with Pandemrix® among healthcare professionals. Material and Methods: A questionnaire for active post-authorization monitoring of adverse events following immunization with the influenza vaccine A (H1N1) was designed and distributed to the vaccinated healthcare professionals working at 3 elected hospital centres in the Northern region, in the period from 26 October 2009 to 31 January 2010. Results: From the 2358 vaccinated healthcare professionals that accepted to participate in this study, 864 (37%) returned back the fulfill questionnaire on time. Among these, 634 (73%) of healthcare professionals experienced at least one adverse event following immunization, but only 8% experienced an unexpected one. The adverse events most frequently reported were expected and very common: local reactions at the injection site (57%), myalgia (31%), fatigue (including asthenia) (24%) and headache (19%). No cases of major episodes, such as death or life-threatening events were reported. Female gender and existence of underlying conditions were independent risk factors to develop at least one adverse event following immunization to the pandemic vaccine. Conclusions: Our work suggests an acceptable safety profile of this pandemic flu vaccine among healthcare professionals. Both frequency and severity of the observed adverse event following immunization do not seem to be higher than expected. |
publishDate |
2013 |
dc.date.none.fl_str_mv |
2013-05-31 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/4102 oai:ojs.www.actamedicaportuguesa.com:article/4102 |
url |
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/4102 |
identifier_str_mv |
oai:ojs.www.actamedicaportuguesa.com:article/4102 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/4102 https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/4102/3234 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Ordem dos Médicos |
publisher.none.fl_str_mv |
Ordem dos Médicos |
dc.source.none.fl_str_mv |
Acta Médica Portuguesa; Vol. 26 No. 2 (2013): March-April; 107-112 Acta Médica Portuguesa; Vol. 26 N.º 2 (2013): Março-Abril; 107-112 1646-0758 0870-399X reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799130638432862208 |